Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Operating Leases (2019 - 2025)

Akebia Therapeutics has reported Operating Leases over the past 7 years, most recently at $3.5 million for Q4 2025.

  • Quarterly Operating Leases changed 0.03% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, changed 0.03% year-over-year, with the annual reading at $3.5 million for FY2025, 0.03% changed from the prior year.
  • Operating Leases was $3.5 million for Q4 2025 at Akebia Therapeutics, down from $4.9 million in the prior quarter.
  • Over five years, Operating Leases peaked at $37.7 million in Q1 2022 and troughed at $2.1 million in Q1 2025.
  • The 5-year median for Operating Leases is $15.7 million (2023), against an average of $18.1 million.
  • Year-over-year, Operating Leases skyrocketed 62.52% in 2022 and then crashed 83.29% in 2025.
  • A 5-year view of Operating Leases shows it stood at $33.7 million in 2021, then dropped by 14.07% to $29.0 million in 2022, then crashed by 69.11% to $8.9 million in 2023, then crashed by 60.36% to $3.5 million in 2024, then increased by 0.03% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Operating Leases are $3.5 million (Q4 2025), $4.9 million (Q3 2025), and $6.3 million (Q2 2025).